Philips announces Living Well Alliance partnership with the British Lung Foundation, furthering its commitment to lung condition management

January 26, 2017

Guildford, United KingdomRoyal Philips (NYSE: PHG; AEX: PHIA) a leading health technology company, has announced a new partnership with the British Lung Foundation (BLF) as one of the founding members of the Living Well Alliance, enabling the 3 million BLF website users, Breathe Easy group members, and helpline callers to make informed choices in accessing specialist support to manage their lung conditions.

 

Long-term lung conditions including COPD and asthma affect a fifth of the UK population. Whilst the majority of lung conditions are not curable, the symptoms can be managed and the quality of life can be improved. Lung diseases are responsible for more than 700,000 hospital admissions and over 6 million inpatient bed-days in the UK each year.*

 

“The British Lung Foundation is pleased to have Philips as one of the founding members of our Living Well Alliance,” said Jason Cater, Director of Fundraising British Lung Foundation. “One in five of the UK population have been diagnosed with a lung disease. We hope our new Living Well Alliance will give those who need lung-health support a simple, single access point to some of the best companies in the country. And allow these specialist companies to reach more potential customers.”

 

“Philips is proud to be a Living Well Alliance partner, supporting the invaluable work of the British Lung Foundation,” said Robin van Rozen, Philips Market Leader Personal Health UK&I. “Philips is dedicated to providing innovative health solutions with a focus on prevention, diagnosis and treatment and actively strives to help lung disease patients in the hospital and at home with its advanced therapy solutions for chronic respiratory disorders, including COPD. Our new partnership with the British Lung Foundation is an important part of our commitment to help patients make informed choices in managing their lung conditions.”

 

The Philips Sleep & Respiratory Care business develops and manufactures a wide range of solutions for patients whether for sleep disordered breathing or chronic respiratory conditions. Philips is a recognised global leader in sleep apnoea therapy (CPAP devices and masks), aerosol drug delivery (nebuliser systems), home ventilation and airway clearance (NIV and cough assist devices) and oxygen therapy (home and portable oxygen concentrators).

 

In addition Philips has just launched its Healthy Home Range, providing innovative solutions to support anyone that suffers from allergies, hay fever or respiratory problems, including a selection of anti-allergen vacuum cleaners. The Philips Anti-Allergen Air Purifier also forms part of the range and can be used day or night to purify the air around you. Featuring Philips innovative VitaShield IPS technology that naturally removes 99.97% of common airborne allergens effectively long term**, enabling its users to enjoy cleaner air at all times.

To learn more about Philips’ work in helping patients with lung conditions, please visit: www.philips.co.uk/respironics. For more information on Philips partnership with the British Lung Foundation,visit: https://www.blf.org.uk/take-action/lets-work-together/living-well-alliance/announcement  

 

*Source: https://statistics.blf.org.uk/

** Particles between 0.3 and 10 microns

For further information, please contact:

Sally Hilson

Philips Group Communications

Mob: +44 (0)7825 454 403    

E-mail: sally.hilson@philips.com

Anti-Allergen Dust Mite Cleaner - Available from Amazon, RRP £230

Anti-Allergen 2-in-1 Lithium Wet & Dry Cordless - Available from Amazon, RRP £260

Anti-Allergen 2-in-1 Lithium Cordless - Available from Amazon, RRP £220

Anti-Allergen Bagless Expert Vacuum Cleaner - Available from Amazon, RRP £260

Anti-Allergen Bagless Ultimate Vacuum Cleaner - Available from Amazon, RRP £310

The Philips Anti-Allergen Air Purifier - Available from Amazon and John Lewis, RRP £390

About Philips Respironics

Philips Respironics is a global leader in the sleep and respiratory care markets, offering solutions in sleep apnea management, oxygen therapy, noninvasive ventilation and respiratory drug delivery. With more than 10 years of cloud-based data sharing experience and analytics for more than 7 million patient lives, Philips Respironics has a long history of leading new innovation in both devices and informatics solutions to help patients sleep and breathe better.

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.